Are statins and macrolides always a dangerous mix?

Not necessarily. The answer depends on which statin, which macrolide and, importantly, the patient.

Macrolide antibiotics are a commonly prescribed short-course therapy in primary care, while statins remain one of Australia’s most widely used long-term medicines.^1,2 That means pharmacists often encounter this combination at the dispensary.

Although interaction alerts are common in both prescribing and dispensing software, not every statin–macrolide combination has been studied or carries the same level of risk.³ Differences in metabolic pathways, transporter inhibition and the quality of available evidence mean management should be individualised rather than based solely on medicine class.

Do all macrolides carry the same risk?

Macrolide antibiotics differ in their potential to interact with statins.^3,4 Clarithromycin and erythromycin inhibit CYP3A4 and P-glycoprotein (P-gp). This can increase exposure to statins that rely on these metabolic pathways, particularly simvastatin and atorvastatin, increasing the risk of myopathy or rhabdomyolysis.^3–5

In contrast, roxithromycin has minimal CYP3A4 inhibitory activity, and azithromycin exerts a weak effect on P-gp, making clinically significant interactions with statins less likely.^3–6

Why do recommendations differ?

Drug interaction resources are generally consistent in identifying the well-established interactions between simvastatin or atorvastatin, and clarithromycin or erythromycin.^3–6

However, some apply broader class-based precautionary warnings, while others provide drug-drug interaction information.^3–5 This reflects both the available evidence and differences in how the resource interprets that evidence. So, recommendations for ‘lower risk’ combinations range from advising patients to monitor for any adverse effects, to providing a maximum statin dose recommendation or temporary statin interruption.^3–8

What should pharmacists do?

When dispensing a macrolide, first identify the patient’s statin. Patients prescribed simvastatin or atorvastatin should temporarily discontinue the statin if clarithromycin or erythromycin is required, or be prescribed an alternative antibiotic. But pravastatin and rosuvastatin are typically lower-risk options.^3–8

Consider the antibiotic indication, treatment duration, statin dose, renal or hepatic impairment, patient age and any history of statin-associated muscle symptoms. Where uncertainty persists, a discussion with the prescriber may be appropriate. Counsel patients to report unexplained muscle pain, weakness or dark urine promptly.^3–8

What’s important to remember?

The question is not whether statins should hide from a macrolide, but which statin, which macrolide and which patient. Understanding the interaction mechanism helps pharmacists interpret different recommendations and make patient-centred decisions.

The Australian Pharmaceutical Formulary and Handbook ‘Pharmacokinetic interaction’ section provides a useful list of drugs that are substrates, inhibitors and inducers of metabolising enzymes or drug transporter proteins to assist in assessing potential pharmacokinetic interactions.

References